Healthcare >> CEO Interviews >> September 24, 2002
MICHAEL ATKIN, Chief Executive Officer of Aegera Therapeutics
Inc., has experience as CEO of Exogen Neurosciences Inc.,
Director of New Products in the Bristol-Myers Squibb Neuroscience
Global Marketing Group and as Vice President, Business
Development of Lederle International Division. During the last 12
years Mr. Atkin has worked specifically in the pharmaceutical
field. With 22 years' experience in management in the United
States, he joined Exogen Neurosciences and forged a deal to form
Aegera through a merger with an Ottawa-based firm, Apoptogen
Inc., and has since negotiated a significant round of financing
for the new company. He was previously Director of New Products
in Bristol-Myers Squibbs Neuroscience Global Marketing Group in
Princeton, New Jersey, where he was responsible for marketing
strategy and pre-market development of drugs for treating stroke,
Parkinson's disease, sleep disorders and migraine. He was also
responsible for lifecycle planning for a marketed $100 million
migraine drug, and for licensing in the area of pain and
migraine. Before joining BMS, Mr. Atkin was Vice President,
Business Development for Lederle International Division. Mr.
Atkin has an MBA in Finance from Columbia University. Profile
Therapeutics, a look at the business and the opportunities today?
Mr. Atkin: Aegera Therapeutics was formed in May 2000 with the
merger of
